Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | PPOX | P50336 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851463 | 0.87 | CHEK1 (0.56) | CHEK1CES1LRRK2TGM2PPOX | |
| SCHEMBL4857624 | 0.83 | CHEK1 (0.60) | CHEK1CES1LRRK2 | |
| SCHEMBL4847603 | 0.77 | CHEK1 (0.45) | CHEK1CES1LRRK2 | |
| SCHEMBL4849523 | 0.75 | CHEK1 (0.62) | CHEK1CES1LRRK2TGM2 | |
| SCHEMBL4857284 | 0.74 | CHEK1 (0.58) | CHEK1CES1LRRK2TGM2 | |
| SCHEMBL4849290 | 0.74 | CHEK1 (0.65) | CHEK1 | |
| SCHEMBL4853307 | 0.73 | CHEK1 (0.65) | CHEK1CES1LRRK2TGM2PPOX | |
| SCHEMBL4856162 | 0.73 | CHEK1 (0.65) | CHEK1CES1LRRK2TGM2PPOX | |
| SCHEMBL4859804 | 0.71 | CHEK1 (0.51) | CHEK1CES1TGM2PPOX | |
| SCHEMBL29485956 | 0.70 | CHEK1 (0.81) | CHEK1CES1LRRK2TGM2PPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 46/4885CES1 1804/4885LRRK2 667/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885CES1 2761/4885LRRK2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.